Barinthus Biotherapeutics (BRNS) Short Interest Ratio & Short Volume → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free BRNS Stock Alerts $1.99 +0.10 (+5.01%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Barinthus Biotherapeutics Short Interest DataCurrent Short Interest9,100 sharesPrevious Short Interest19,000 sharesChange Vs. Previous Month-52.11%Dollar Volume Sold Short$20,202.00Short Interest Ratio0.4 Days to CoverLast Record DateMay 15, 2024Outstanding Shares39,033,000 sharesFloat Size35,990,000 sharesShort Percent of Float0.03%Today's Trading Volume13,000 sharesAverage Trading Volume19,261 sharesToday's Volume Vs. Average67% Short Selling Barinthus Biotherapeutics ? Sign up to receive the latest short interest report for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBRNS Short Interest Over TimeBRNS Days to Cover Over TimeBRNS Percentage of Float Shorted Over Time Ad Smallcaps DailyIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution Barinthus Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20249,100 shares $20,202.00 -52.1%0.0%0.4 $2.22 4/30/202419,000 shares $38,950.00 +34.8%0.1%0.8 $2.05 4/15/202414,100 shares $37,252.20 +39.6%0.0%0.6 $2.64 3/31/202410,100 shares $24,038.00 -15.1%0.0%0.5 $2.38 3/15/202411,900 shares $29,393.00 -3.3%0.0%0.8 $2.47 2/29/202412,300 shares $34,809.00 -12.8%0.0%0.8 $2.83 2/15/202414,100 shares $34,968.00 -55.8%0.0%1.2 $2.48 1/31/202431,900 shares $87,725.00 No Change0.1%1.3 $2.75 BRNS Short Interest - Frequently Asked Questions What is Barinthus Biotherapeutics' current short interest? Short interest is the volume of Barinthus Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 9,100 shares of BRNS short. 0.03% of Barinthus Biotherapeutics' shares are currently sold short. Learn More on Barinthus Biotherapeutics' current short interest. What is a good short interest percentage for Barinthus Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Barinthus Biotherapeutics' floating shares are currently sold short. Is Barinthus Biotherapeutics' short interest increasing or decreasing? Barinthus Biotherapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 9,100 shares, a drop of 52.1% from the previous total of 19,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Barinthus Biotherapeutics' float size? Barinthus Biotherapeutics currently has issued a total of 39,033,000 shares. Some of Barinthus Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Barinthus Biotherapeutics currently has a public float of 35,990,000 shares. How does Barinthus Biotherapeutics' short interest compare to its competitors? 0.03% of Barinthus Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Barinthus Biotherapeutics: Kamada Ltd. (0.11%), Atea Pharmaceuticals, Inc. (2.53%), Revance Therapeutics, Inc. (11.96%), ESSA Pharma Inc. (2.06%), XOMA Co. (2.09%), Mersana Therapeutics, Inc. (7.35%), Vanda Pharmaceuticals Inc. (5.08%), CorMedix Inc. (17.61%), Inozyme Pharma, Inc. (6.46%), Adlai Nortye Ltd. (0.03%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Barinthus Biotherapeutics stock? Short selling BRNS is an investing strategy that aims to generate trading profit from Barinthus Biotherapeutics as its price is falling. BRNS shares are trading up $0.09 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Barinthus Biotherapeutics? A short squeeze for Barinthus Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BRNS, which in turn drives the price of the stock up even further. How often is Barinthus Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BRNS, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: MacroGenics Short Interest Data ADC Therapeutics Short Interest Data Amarin Short Interest Data Nature's Sunshine Products Short Interest Data CorMedix Short Interest Data Mersana Therapeutics Short Interest Data XOMA Short Interest Data Enanta Pharmaceuticals Short Interest Data Foghorn Therapeutics Short Interest Data ESSA Pharma Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BRNS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.